开云app官网登录入口网页版-官方正版

#Pembro#

98篇内容 | 2209人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1787043, encodeId=85fa1e870433f, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=Clin Cancer Res：Pembrolizumab单药治疗晚期肝细胞癌的效果, objectType=article, longId=724681, objectId=ae69e2468173, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae69e2468173, replyNumber=0, likeNumber=81, createdTime=2023-01-28, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae69e2468173, moduleTitle=Clin Cancer Res：Pembrolizumab单药治疗晚期肝细胞癌的效果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ae69e2468173)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787045, encodeId=ef681e87045b0, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=Eur Urol：Pembrolizumab+Axitinib与Sunitinib治疗晚期肾细胞癌的生活质量比较, objectType=article, longId=736966, objectId=ac21e36966ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac21e36966ab, replyNumber=0, likeNumber=97, createdTime=2023-06-05, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac21e36966ab, moduleTitle=Eur Urol：Pembrolizumab+Axitinib与Sunitinib治疗晚期肾细胞癌的生活质量比较, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ac21e36966ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787041, encodeId=380d1e870416e, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=Oncologist：Pembrolizumab（帕博利珠单抗）联合CAPOX（奥沙利铂+卡培他滨）治疗晚期胆管癌（BTC）的疗效和安全性, objectType=article, longId=301205, objectId=7d6a3012059f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d6a3012059f, replyNumber=0, likeNumber=98, createdTime=2022-12-27, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d6a3012059f, moduleTitle=Oncologist：Pembrolizumab（帕博利珠单抗）联合CAPOX（奥沙利铂+卡培他滨）治疗晚期胆管癌（BTC）的疗效和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7d6a3012059f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787038, encodeId=98ad1e87038b5, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=J Clin Oncol：KEYNOTE-158研究表明Pembrolizumab（帕博利珠单抗）治疗经治MSI-H/dMMR子宫内膜癌患者疗效显著, objectType=article, longId=293562, objectId=0e1f293562ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e1f293562ed, replyNumber=0, likeNumber=86, createdTime=2022-06-28, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e1f293562ed, moduleTitle=J Clin Oncol：KEYNOTE-158研究表明Pembrolizumab（帕博利珠单抗）治疗经治MSI-H/dMMR子宫内膜癌患者疗效显著, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0e1f293562ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787040, encodeId=f5361e87040b3, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=Transl Lung Cancer Res: Pembrolizumab（帕博利珠单抗）单药或联合治疗晚期非小细胞肺癌伴骨转移患者的疗效, objectType=article, longId=295254, objectId=ccd329525402, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccd329525402, replyNumber=0, likeNumber=89, createdTime=2023-01-24, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccd329525402, moduleTitle=Transl Lung Cancer Res: Pembrolizumab（帕博利珠单抗）单药或联合治疗晚期非小细胞肺癌伴骨转移患者的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ccd329525402)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787042, encodeId=e32d1e870429e, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=Front Oncol：真实世界评估PD-L1≧50%的晚期NSCLC患者一线pembrolizumab（帕博利珠单抗）单药治疗的长期疗效, objectType=article, longId=301707, objectId=d31c301e07bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d31c301e07bd, replyNumber=0, likeNumber=93, createdTime=2022-07-16, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d31c301e07bd, moduleTitle=Front Oncol：真实世界评估PD-L1≧50%的晚期NSCLC患者一线pembrolizumab（帕博利珠单抗）单药治疗的长期疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d31c301e07bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787044, encodeId=76691e87044da, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=Thorac Cancer：Pembrolizumab（帕博利珠单抗）单药一线治疗PD-L1高表达老年NSCLC的疗效, objectType=article, longId=726424, objectId=b321e2642494, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b321e2642494, replyNumber=0, likeNumber=104, createdTime=2022-10-04, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b321e2642494, moduleTitle=Thorac Cancer：Pembrolizumab（帕博利珠单抗）单药一线治疗PD-L1高表达老年NSCLC的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b321e2642494)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787034, encodeId=0d481e870345d, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=2020年ASCO-SITC：恶病质与接受Pembrolizumab的晚期肺癌患者的生存率相关, objectType=article, longId=221034, objectId=5e2522103406, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e2522103406, replyNumber=0, likeNumber=77, createdTime=2022-06-26, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e2522103406, moduleTitle=2020年ASCO-SITC：恶病质与接受Pembrolizumab的晚期肺癌患者的生存率相关, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5e2522103406)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787037, encodeId=b5d61e8703754, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=NICE推荐pembrolizumab单药作为3期黑色素瘤的辅助疗法, objectType=article, longId=292248, objectId=3be42922488a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3be42922488a, replyNumber=0, likeNumber=101, createdTime=2022-04-26, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3be42922488a, moduleTitle=NICE推荐pembrolizumab单药作为3期黑色素瘤的辅助疗法, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3be42922488a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787039, encodeId=cd161e870393b, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=J Clin Oncol：Afatinib（阿法替尼）联合Pembrolizumab（帕博利珠单抗）治疗复发或转移性头颈鳞状细胞癌（HNSCC）患者的疗效：ALPHA研究, objectType=article, longId=294454, objectId=3f302944546a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f302944546a, replyNumber=0, likeNumber=97, createdTime=2022-01-28, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f302944546a, moduleTitle=J Clin Oncol：Afatinib（阿法替尼）联合Pembrolizumab（帕博利珠单抗）治疗复发或转移性头颈鳞状细胞癌（HNSCC）患者的疗效：ALPHA研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3f302944546a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787028, encodeId=93691e87028d0, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=Clin Cancer Res：标准剂量Pembrolizumab 联合不同剂量Ipilimumab治疗晚期黑色素瘤的疗效：KEYNOTE-029 队列1C。, objectType=article, longId=213761, objectId=ae12213e61f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae12213e61f4, replyNumber=0, likeNumber=81, createdTime=2021-07-11, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae12213e61f4, moduleTitle=Clin Cancer Res：标准剂量Pembrolizumab 联合不同剂量Ipilimumab治疗晚期黑色素瘤的疗效：KEYNOTE-029 队列1C。, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ae12213e61f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787033, encodeId=156b1e870336a, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=J Immunother Cancer：Pembrolizumab（帕博利珠单抗）联合低剂量卡铂治疗复发铂耐药的卵巢、输卵管、原发性腹膜癌的疗效, objectType=article, longId=217313, objectId=046121e3130e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=046121e3130e, replyNumber=0, likeNumber=88, createdTime=2022-04-07, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=046121e3130e, moduleTitle=J Immunother Cancer：Pembrolizumab（帕博利珠单抗）联合低剂量卡铂治疗复发铂耐药的卵巢、输卵管、原发性腹膜癌的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=046121e3130e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787032, encodeId=2b021e870323e, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=Gastric Cancer：帕博利珠单抗（Pembrolizumab）vs 紫杉醇治疗既往治疗过PD-L1阳性胃或胃食管连接处癌的疗效：III期临床研究KEYNOTE‑061的2年更新结果, objectType=article, longId=216988, objectId=2a7f21698850, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a7f21698850, replyNumber=0, likeNumber=84, createdTime=2021-12-08, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a7f21698850, moduleTitle=Gastric Cancer：帕博利珠单抗（Pembrolizumab）vs 紫杉醇治疗既往治疗过PD-L1阳性胃或胃食管连接处癌的疗效：III期临床研究KEYNOTE‑061的2年更新结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2a7f21698850)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787024, encodeId=b15a1e87024ac, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=J Immunother Cancer: IDO抑制剂indoximod联合PD1抑制剂帕博利珠单抗（pembrolizumab）治疗晚期黑色素瘤的疗效和安全性, objectType=article, longId=212747, objectId=5467212e47b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5467212e47b0, replyNumber=0, likeNumber=101, createdTime=2021-08-18, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5467212e47b0, moduleTitle=J Immunother Cancer: IDO抑制剂indoximod联合PD1抑制剂帕博利珠单抗（pembrolizumab）治疗晚期黑色素瘤的疗效和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5467212e47b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787036, encodeId=56de1e87036c3, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=Thorac Cancer：多中心回顾性研究比较pembrolizumab单药或联合化疗治疗非小细胞肺癌的疗效, objectType=article, longId=221635, objectId=7c93221635a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c93221635a0, replyNumber=0, likeNumber=82, createdTime=2021-12-23, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c93221635a0, moduleTitle=Thorac Cancer：多中心回顾性研究比较pembrolizumab单药或联合化疗治疗非小细胞肺癌的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7c93221635a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787026, encodeId=4f091e87026fb, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=Eur Urol：抗生素治疗对接受新辅助Pembrolizumab治疗的肌层浸润性膀胱癌患者是否有不利影响？ , objectType=article, longId=213080, objectId=46dd21308067, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46dd21308067, replyNumber=0, likeNumber=80, createdTime=2021-11-13, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46dd21308067, moduleTitle=Eur Urol：抗生素治疗对接受新辅助Pembrolizumab治疗的肌层浸润性膀胱癌患者是否有不利影响？ , moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=46dd21308067)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787035, encodeId=afca1e8703589, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果, objectType=article, longId=221052, objectId=063622105235, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=063622105235, replyNumber=0, likeNumber=92, createdTime=2022-04-13, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=063622105235, moduleTitle=JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=063622105235)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787025, encodeId=388f1e8702541, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=Ann Oncol：帕博利珠单抗（pembrolizumab）联合培美曲塞+铂类治疗转移性非鳞状非小细胞肺癌患者的疗效和安全性：KEYNOTE-189, objectType=article, longId=212750, objectId=8752212e509b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8752212e509b, replyNumber=0, likeNumber=87, createdTime=2022-02-11, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8752212e509b, moduleTitle=Ann Oncol：帕博利珠单抗（pembrolizumab）联合培美曲塞+铂类治疗转移性非鳞状非小细胞肺癌患者的疗效和安全性：KEYNOTE-189, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8752212e509b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787021, encodeId=0b431e87021f0, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=JCO：Pembrolizumab 联合Ipilimumab治疗PD1/PDL1抑制剂失败黑素色瘤的疗效和安全性, objectType=article, longId=211042, objectId=63df21104261, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63df21104261, replyNumber=0, likeNumber=77, createdTime=2021-07-25, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63df21104261, moduleTitle=JCO：Pembrolizumab 联合Ipilimumab治疗PD1/PDL1抑制剂失败黑素色瘤的疗效和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=63df21104261)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787027, encodeId=81d81e8702718, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=BJU Int：组织学变异对pembrolizumab治疗的尿道癌患者结果的影响, objectType=article, longId=213553, objectId=fca92135533b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fca92135533b, replyNumber=0, likeNumber=93, createdTime=2022-02-01, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fca92135533b, moduleTitle=BJU Int：组织学变异对pembrolizumab治疗的尿道癌患者结果的影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fca92135533b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

Pembro

2020-05-29

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

Clin Cancer Res：Pembrolizumab单药治疗晚期肝细胞癌的效果

2023-01-28

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

Eur Urol：Pembrolizumab+Axitinib与Sunitinib治疗晚期肾细胞癌的生活质量比较

2023-06-05

heli0118 (审核中...)

前往app查看评论内容

#Pembro#

Oncologist：Pembrolizumab（帕博利珠单抗）联合CAPOX（奥沙利铂+卡培他滨）治疗晚期胆管癌（BTC）的疗效和安全性

2022-12-27

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

J Clin Oncol：KEYNOTE-158研究表明Pembrolizumab（帕博利珠单抗）治疗经治MSI-H/dMMR子宫内膜癌患者疗效显著

2022-06-28

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

Transl Lung Cancer Res: Pembrolizumab（帕博利珠单抗）单药或联合治疗晚期非小细胞肺癌伴骨转移患者的疗效

2023-01-24

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

Front Oncol：真实世界评估PD-L1≧50%的晚期NSCLC患者一线pembrolizumab（帕博利珠单抗）单药治疗的长期疗效

2022-07-16

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

Thorac Cancer：Pembrolizumab（帕博利珠单抗）单药一线治疗PD-L1高表达老年NSCLC的疗效

2022-10-04

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

2020年ASCO-SITC：恶病质与接受Pembrolizumab的晚期肺癌患者的生存率相关

2022-06-26

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

NICE推荐pembrolizumab单药作为3期黑色素瘤的辅助疗法

2022-04-26

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

J Clin Oncol：Afatinib（阿法替尼）联合Pembrolizumab（帕博利珠单抗）治疗复发或转移性头颈鳞状细胞癌（HNSCC）患者的疗效：ALPHA研究

2022-01-28

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

Clin Cancer Res：标准剂量Pembrolizumab 联合不同剂量Ipilimumab治疗晚期黑色素瘤的疗效：KEYNOTE-029 队列1C。

2021-07-11

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

J Immunother Cancer：Pembrolizumab（帕博利珠单抗）联合低剂量卡铂治疗复发铂耐药的卵巢、输卵管、原发性腹膜癌的疗效

2022-04-07

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

Gastric Cancer：帕博利珠单抗（Pembrolizumab）vs 紫杉醇治疗既往治疗过PD-L1阳性胃或胃食管连接处癌的疗效：III期临床研究KEYNOTE‑061的2年更新结果

2021-12-08

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

J Immunother Cancer: IDO抑制剂indoximod联合PD1抑制剂帕博利珠单抗（pembrolizumab）治疗晚期黑色素瘤的疗效和安全性

2021-08-18

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

Thorac Cancer：多中心回顾性研究比较pembrolizumab单药或联合化疗治疗非小细胞肺癌的疗效

2021-12-23

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

Eur Urol：抗生素治疗对接受新辅助Pembrolizumab治疗的肌层浸润性膀胱癌患者是否有不利影响？

2021-11-13

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果

2022-04-13

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

Ann Oncol：帕博利珠单抗（pembrolizumab）联合培美曲塞+铂类治疗转移性非鳞状非小细胞肺癌患者的疗效和安全性：KEYNOTE-189

2022-02-11

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

JCO：Pembrolizumab 联合Ipilimumab治疗PD1/PDL1抑制剂失败黑素色瘤的疗效和安全性

2021-07-25

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

BJU Int：组织学变异对pembrolizumab治疗的尿道癌患者结果的影响

2022-02-01

科室
- - 订阅+
  - 更多科室
工具
服务